United Therapeutics Corp
UTHR440.000USD
-5.380-1.21%
Fechamento 10/10, 16:00（ET）Cotações atrasadas em 15 min
19.89BValor de mercado
16.02P/L TTM
Mais detalhes de United Therapeutics Corp Empresa
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.
Informações de United Therapeutics Corp
Código da empresaUTHR
Nome da EmpresaUnited Therapeutics Corp
Data de listagemJun 17, 1999
CEODr. Martine A. Rothblatt
Número de funcionários1305
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 17
Endereço1000 Spring St
CidadeSILVER SPRING
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal20910
Telefone13016089292
Sitehttps://www.unither.com/
Código da empresaUTHR
Data de listagemJun 17, 1999
CEODr. Martine A. Rothblatt
Executivos da empresa United Therapeutics Corp
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Martine A. Rothblatt
Dr. Martine A. Rothblatt
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
666.42K
--
Mr. Paul A. Mahon, J.D.
Mr. Paul A. Mahon, J.D.
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
36.78K
--
Mr. Richard A. Giltner
Mr. Richard A. Giltner
Independent Director
Independent Director
20.57K
+6.14%
Prof. Nilda Mesa, J.D.
Prof. Nilda Mesa, J.D.
Independent Director
Independent Director
5.47K
+12.08%
The Hon. Dr. Louis W. Sullivan, M.D.
The Hon. Dr. Louis W. Sullivan, M.D.
Independent Director
Independent Director
3.20K
--
Mr. Michael Benkowitz
Mr. Michael Benkowitz
President, Chief Operating Officer
President, Chief Operating Officer
2.65K
+2.76%
Mr. Christopher Patusky, J.D.
Mr. Christopher Patusky, J.D.
Lead Independent Vice Chairman of the Board
Lead Independent Vice Chairman of the Board
2.59K
+29.50%
Ms. Jan Malcolm
Ms. Jan Malcolm
Director
Director
520.00
-57.38%
Gov. Thomas G. (Tommy) Thompson, J.D.
Gov. Thomas G. (Tommy) Thompson, J.D.
Independent Director
Independent Director
--
--
Mr. Christopher A. Causey
Mr. Christopher A. Causey
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Martine A. Rothblatt
Dr. Martine A. Rothblatt
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
666.42K
--
Mr. Paul A. Mahon, J.D.
Mr. Paul A. Mahon, J.D.
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
36.78K
--
Mr. Richard A. Giltner
Mr. Richard A. Giltner
Independent Director
Independent Director
20.57K
+6.14%
Prof. Nilda Mesa, J.D.
Prof. Nilda Mesa, J.D.
Independent Director
Independent Director
5.47K
+12.08%
The Hon. Dr. Louis W. Sullivan, M.D.
The Hon. Dr. Louis W. Sullivan, M.D.
Independent Director
Independent Director
3.20K
--
Mr. Michael Benkowitz
Mr. Michael Benkowitz
President, Chief Operating Officer
President, Chief Operating Officer
2.65K
+2.76%
Detalhamento da receita
Moeda: USDAtualizado em: seg, 6 de out
Moeda: USDAtualizado em: seg, 6 de out
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por EmpresaUSD
Nome
Receita
Proporção
Tyvaso DPI
315.20M
39.47%
Nebulized Tyvaso
168.30M
21.07%
Remodulin
155.70M
19.50%
Orenitram
123.90M
15.51%
Unituxin
61.40M
7.69%
Outro
-25.90M
-3.24%
Por RegiãoUSD
Nome
Receita
Proporção
United States
798.60M
100.00%
Rest of World
38.80M
4.86%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Tyvaso DPI
315.20M
39.47%
Nebulized Tyvaso
168.30M
21.07%
Remodulin
155.70M
19.50%
Orenitram
123.90M
15.51%
Unituxin
61.40M
7.69%
Outro
-25.90M
-3.24%
Distribuição de ações
Atualizado em: sex, 15 de ago
Atualizado em: sex, 15 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
9.79%
BlackRock Institutional Trust Company, N.A.
9.59%
Avoro Capital Advisors LLC
5.24%
State Street Global Advisors (US)
4.79%
Renaissance Technologies LLC
4.69%
Outro
65.89%
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
9.79%
BlackRock Institutional Trust Company, N.A.
9.59%
Avoro Capital Advisors LLC
5.24%
State Street Global Advisors (US)
4.79%
Renaissance Technologies LLC
4.69%
Outro
65.89%
Tipos de investidores
Investidores
Proporção
Investment Advisor
42.73%
Investment Advisor/Hedge Fund
37.74%
Hedge Fund
9.19%
Pension Fund
4.79%
Individual Investor
1.75%
Research Firm
1.73%
Bank and Trust
1.44%
Sovereign Wealth Fund
1.25%
Venture Capital
0.46%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
1330
44.91M
99.30%
-3.12M
2025Q2
1338
46.42M
102.62%
-2.51M
2025Q1
1369
46.67M
103.49%
-1.81M
2024Q4
1344
46.07M
102.60%
-3.00M
2024Q3
1278
45.38M
101.97%
-7.63M
2024Q2
1219
48.02M
108.26%
-2.92M
2024Q1
1151
47.12M
106.59%
-2.41M
2023Q4
1127
46.52M
99.01%
-2.26M
2023Q3
1094
46.35M
98.80%
-3.96M
2023Q2
1068
46.82M
99.96%
-3.45M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
4.43M
9.79%
-8.97K
-0.20%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.34M
9.59%
-138.61K
-3.10%
Jun 30, 2025
Avoro Capital Advisors LLC
2.37M
5.24%
-305.00K
-11.40%
Jun 30, 2025
State Street Global Advisors (US)
2.17M
4.79%
-63.20K
-2.83%
Jun 30, 2025
Renaissance Technologies LLC
2.12M
4.69%
+12.10K
+0.57%
Jun 30, 2025
Wellington Management Company, LLP
1.44M
3.19%
-583.48K
-28.79%
Jun 30, 2025
AQR Capital Management, LLC
1.27M
2.82%
+364.71K
+40.15%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.20M
2.65%
-23.63K
-1.93%
Jun 30, 2025
LSV Asset Management
864.62K
1.91%
-37.70K
-4.18%
Jun 30, 2025
Invesco Capital Management LLC
821.69K
1.82%
+445.52K
+118.44%
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: seg, 6 de out
Atualizado em: seg, 6 de out
Nome
Proporção
Invesco Biotechnology & Genome ETF
4.57%
First Trust NASDAQ Pharmaceuticals ETF
3.59%
First Trust NYSE Arca Biotechnology Index Fund
3.34%
Formidable Fortress ETF
2.96%
Franklin Genomic Advancements ETF
2.73%
SPDR S&P Biotech ETF
2.57%
Inspire Faithward Mid Cap Momentum ETF
2.52%
Invesco S&P MidCap Quality ETF
2.42%
Invesco Pharmaceuticals ETF
2.3%
First Trust Health Care Alphadex Fund
2.28%
Ver Mais
Invesco Biotechnology & Genome ETF
Proporção4.57%
First Trust NASDAQ Pharmaceuticals ETF
Proporção3.59%
First Trust NYSE Arca Biotechnology Index Fund
Proporção3.34%
Formidable Fortress ETF
Proporção2.96%
Franklin Genomic Advancements ETF
Proporção2.73%
SPDR S&P Biotech ETF
Proporção2.57%
Inspire Faithward Mid Cap Momentum ETF
Proporção2.52%
Invesco S&P MidCap Quality ETF
Proporção2.42%
Invesco Pharmaceuticals ETF
Proporção2.3%
First Trust Health Care Alphadex Fund
Proporção2.28%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
